Formulation and announcement of a new medium-term management plan beginning in the fiscal year ending September 2020

「Fuji Pharmaceutical Co., Ltd. Group has formulated Long-Term Vision 2035 as its vision of continuing to create value into the future by further cycling the cycle of growth and contribution, its management philosophy. To realize Long-Term Vision 2035, over the next 5 years it is pursuing the following 4 growth strategies as its medium-term management plan: expanding its contribution to women's healthcare; expanding its contribution through the biosimilars business; generating earnings contributions through the global CMO business; and preparing for and identifying the next growth drivers. These are supported by 3 initiatives to strengthen the management foundation: strengthening human resources; upgrading organizational capabilities; and promoting digitalization.」

「In the final year of this medium-term management plan, under the theme Fujiらしくをあたらしく, the Group is pursuing its growth strategy toward 2030. This includes strengthening our core women's healthcare and acute-care healthcare fields, accelerating business development in the ASEAN and North American markets, and enriching our pipeline of new drugs, biosimilars and generics so that it can be expanded further over the subsequent five years.」

「Against this backdrop, as its 2030 Vision, the Group has set out its desired state 10 years from now: contributing to the well-being of women worldwide; advancing from Toyama, the home of pharmaceuticals, into the global market; and becoming a company where being the world's happiest company and contributing to society are integrated. To realize this vision, we are formulating a medium-term management plan as a roadmap showing the path toward the fiscal year ending September 2024, the interim point for achieving the vision.」

「Against this backdrop, as its 2030 Vision, the Group has set out its desired state 10 years from now: contributing to the well-being of women worldwide; advancing from Toyama, the home of pharmaceuticals, into the global market; and becoming a company where being the world's happiest company and contributing to society are integrated. To realize this vision, we are formulating a medium-term management plan as a roadmap showing the path toward the fiscal year ending September 2024, the interim point for achieving the vision.」

「Against this backdrop, as its 2030 Vision, the Group has set out its desired state 10 years from now: contributing to the well-being of women worldwide; advancing from Toyama, the home of pharmaceuticals, into the global market; and becoming a company where being the world's happiest company and contributing to society are integrated. To realize this vision, we are formulating a medium-term management plan as a roadmap showing the path toward the fiscal year ending September 2024, the interim point for achieving the vision.」

「To ensure the realization of the 2030 Vision, we established the five-year medium-term management plan, Fujiらしくをあたらしく, ending in the fiscal year ending September 2024.」

「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「Under these circumstances, the Fuji Pharma Group established a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「To ensure the realization of the 2030 Vision, we established the five-year medium-term management plan, Fujiらしくをあたらしく, ending in the fiscal year ending September 2024.」

「Against this backdrop, as its 2030 Vision, the Group has set out its desired state 10 years from now: contributing to the well-being of women worldwide; advancing from Toyama, the home of pharmaceuticals, into the global market; and becoming a company where being the world's happiest company and contributing to society are integrated. To realize this vision, we formulated a new medium-term management plan as a roadmap showing the path toward the fiscal year ending September 2024, the interim point for achieving the vision.」

「Against this backdrop, as its 2030 Vision, the Group has set out its desired state 10 years from now: contributing to the well-being of women worldwide; advancing from Toyama, the home of pharmaceuticals, into the global market; and becoming a company where being the world's happiest company and contributing to society are integrated. To realize this vision, we formulated a new medium-term management plan as a roadmap showing the path toward the fiscal year ending September 2024, the interim point for achieving the vision.」

「Under these circumstances, the Fuji Pharma Group established a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, the midpoint for realizing its 2030 Vision: "Contributing to the well-being of women around the world," "Entering the global market from Toyama, the home of medicine," and "Integrating the world's happiest company with social contribution" as the desired state 10 years from now. Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」

「We have established the five-year medium-term management plan, Fujiらしくをあたらしく, ending in the fiscal year ending September 2024. The plan identifies the following as growth scenarios: enhancing our position in women's healthcare, a priority field; evolving into a sustainable contrast media business; establishing a biosimilars business; strengthening our overseas business; and establishing the management foundation to support these initiatives.」

「The medium-term management plan beginning in the fiscal year ending September 2020 is currently being formulated based on the long-term vision of Iwai Takayuki (岩井 孝之), who became president in October 2019, and is scheduled to be announced when the financial results for the first half of the fiscal year ending September 2020 are released.」